Status: Recruiting
Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
This phase II trial tests how well atezolizumab works in treating patients with human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma that is able to be removed with surgery (resectable). Immunotherapy with atezolizumab, may include changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Emory UniversityUpdated: Aug 5, 2026Locations: 1
Eligibility criteria
The subject is >= 18 years old on the day of consent [+28]
Symptomatic, untreated, or actively progressing central nervous system (CNS) met... [+31]